Last reviewed · How we verify
PEG -Intron
PEG-Intron is a pegylated interferon alfa-2b that enhances and prolongs the antiviral immune response by binding to interferon receptors on immune cells.
PEG-Intron is a pegylated interferon alfa-2b that enhances and prolongs the antiviral immune response by binding to interferon receptors on immune cells. Used for Chronic hepatitis C virus (HCV) infection, typically in combination with ribavirin, Chronic hepatitis B virus (HBV) infection.
At a glance
| Generic name | PEG -Intron |
|---|---|
| Also known as | PEG interferon Alfa-2b 0.5mcg/kg weekly |
| Sponsor | Beth Israel Deaconess Medical Center |
| Drug class | Pegylated interferon alfa |
| Target | Interferon-alpha receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Virology |
| Phase | FDA-approved |
Mechanism of action
PEG-Intron is interferon alfa-2b conjugated with polyethylene glycol (PEG), which slows clearance and extends half-life compared to unmodified interferon. It activates natural killer cells, macrophages, and T lymphocytes to suppress viral replication and has immunomodulatory effects. The pegylation allows for less frequent dosing while maintaining therapeutic efficacy.
Approved indications
- Chronic hepatitis C virus (HCV) infection, in combination with ribavirin
- Chronic hepatitis B virus (HBV) infection
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Headache
- Neutropenia
- Thrombocytopenia
- Depression/mood changes
- Injection site reactions
- Anemia
Key clinical trials
- Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia (PHASE2)
- Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma (PHASE2)
- A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV (NA)
- Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors (NA)
- Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer (PHASE1)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients (PHASE3)
- A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C (PHASE1)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PEG -Intron CI brief — competitive landscape report
- PEG -Intron updates RSS · CI watch RSS
- Beth Israel Deaconess Medical Center portfolio CI